KNSA (Kiniksa Pharmaceuticals International) Interest Expense: $0.0 Mil (TTM As of Mar. 2026)


KNSA Kiniksa Pharmaceuticals International PLC KNSA
54 GF Score
Price $64.53
GF Value $48.22
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Interest Expense?

Kiniksa Pharmaceuticals International KNSA +2.62% 54 Interest Expense is $0.0 Mil as of Mar. 2026. GuruFocus rates KNSA with a GF Score™ of 54/100 and a GF Value™ of $48.22 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kiniksa Pharmaceuticals International's interest expense for the three months ended in Mar. 2026 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kiniksa Pharmaceuticals International's Operating Income for the three months ended in Mar. 2026 was $ 29.3 Mil. Kiniksa Pharmaceuticals International's Interest Expense for the three months ended in Mar. 2026 was $ 0.0 Mil. GuruFocus does not calculate Kiniksa Pharmaceuticals International's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kiniksa Pharmaceuticals International  (NAS:KNSA) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kiniksa Pharmaceuticals International's Interest Expense for the three months ended in Mar. 2026 was $0.0 Mil. Its Operating Income for the three months ended in Mar. 2026 was $29.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $5.9 Mil.

Kiniksa Pharmaceuticals International's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Kiniksa Pharmaceuticals International's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Kiniksa Pharmaceuticals International PLC has enough cash to cover all of its debt. Its financial situation is stable.

Kiniksa Pharmaceuticals International Interest Expense Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Interest Expense Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kiniksa Pharmaceuticals International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KNSA
54GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiniksa Pharmaceuticals International Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.0 Mil mean?
Kiniksa Pharmaceuticals International (KNSA) has a Interest Expense of $0.0 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kiniksa Pharmaceuticals International and its competitors.
Is Kiniksa Pharmaceuticals International's Interest Expense too high?
Kiniksa Pharmaceuticals International's current Interest Expense is $0.0 Mil. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Interest Expense compare to INDV and AMRX?
Kiniksa Pharmaceuticals International's Interest Expense of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kiniksa Pharmaceuticals International and its competitors. Kiniksa Pharmaceuticals International's current Interest Expense is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.22, compared to a current price of $64.53 — trading 33.8% above its estimated fair value. The current Interest Expense is $0.0 Mil. Kiniksa Pharmaceuticals International's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Interest Expense is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $64.53 is trading 33.8% above its estimated GF Value™ of $48.22. GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.

Key valuation signals for KNSA:

  • Interest Expense: $0.0 Mil
  • GF Value™: $48.22 vs. price of $64.53 (33.8% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
54GF Score

Get the complete analysis for KNSA

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$64.53
Price
$48.22
GF Value